|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash on hand and in banks | ||||||||||||||||||||
| Interest bearing cash deposits | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Debt securities, available-for-sale | ||||||||||||||||||||
| Debt securities, held-to-maturity | ||||||||||||||||||||
| Total debt securities | ||||||||||||||||||||
| Loans held for sale, at fair value | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| Other real estate owned and foreclosed assets | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Deferred tax asset, net | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Federal Home Loan Bank stock, at cost | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Non-interest bearing deposits | ||||||||||||||||||||
| Interest bearing deposits | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| Federal Home Loan Bank advances | ||||||||||||||||||||
| FRB Bank Term Funding | ||||||||||||||||||||
| Other borrowed funds | ||||||||||||||||||||
| Finance lease liabilities | ||||||||||||||||||||
| Subordinated debentures | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Commitments and Contingent Liabilities | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Preferred shares, $0.01 par value per share, 1,000,000 shares authorized, none issued or outstanding | ||||||||||||||||||||
| Common stock, $0.01 par value per share, 234,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Number of common stock shares issued (in shares) | ||||||||||||||||||||
| Number of common stock shares outstanding (in shares) | ||||||||||||||||||||
| Common Stock, Shares Authorized | ||||||||||||||||||||
Loading...
